United Therapeutics Corporation
Martine A Rothblatt (Chairperson & CEO) sells UTHR shares
AI-generated summary
Chairperson & CEO, Director Martine A Rothblatt exercised options for 9,500 shares at an average price of $117.76 valued at $1,118,720 and sold 9,500 shares at an average price of $601.92 valued at $5,718,264 indirectly by Trust. After these transactions, the insider held 324,443 shares indirectly by Trust. The transactions were made under a Rule 10b5-1 trading plan adopted on November 7, 2025.
Key facts
- Insider
- Martine A Rothblatt · Chairperson & CEO, Director
Rule 10b5-1 plan · adopted Nov 7, 2025
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | M · exercise or conversion of a derivativeFootnotes F1, F2 | +9,500 | $117.76 | $1,118,720.00 | 333,943 | Indirect (by Trust) |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F3, F2 | −426 | $598.68 | $255,035.98 | 333,517 | Indirect (by Trust) |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F4, F2 | −1,284 | $599.80 | $770,145.38 | 332,233 | Indirect (by Trust) |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F5, F2 | −2,202 | $600.73 | $1,322,802.84 | 330,031 | Indirect (by Trust) |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F6, F2 | −1,440 | $601.54 | $866,213.42 | 328,591 | Indirect (by Trust) |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F7, F2 | −1,261 | $602.79 | $760,116.30 | 327,330 | Indirect (by Trust) |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F8, F2 | −1,927 | $603.70 | $1,163,326.62 | 325,403 | Indirect (by Trust) |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F9, F2 | −840 | $604.65 | $507,907.09 | 324,563 | Indirect (by Trust) |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F10, F2 | −120 | $605.97 | $72,716.40 | 324,443 | Indirect (by Trust) |
| Nov 3, 2026 | M · exercise or conversion of a derivativeStock OptionFootnotes F1, F14, F15 | −9,500 | $0.00 | $0.00 | 100,410 | Indirect (by Trust) |
Footnotes
- F1 This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10 This transaction was executed in multiple trades at prices ranging from $605.78 to $606.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11 Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F12 Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F13 Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F14 These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
- F15 Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2 Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3 This transaction was executed in multiple trades at prices ranging from $598.10 to $599.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4 This transaction was executed in multiple trades at prices ranging from $599.18 to $600.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5 This transaction was executed in multiple trades at prices ranging from $600.20 to $601.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6 This transaction was executed in multiple trades at prices ranging from $601.215 to $602.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7 This transaction was executed in multiple trades at prices ranging from $602.29 to $603.275. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8 This transaction was executed in multiple trades at prices ranging from $603.29 to $604.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9 This transaction was executed in multiple trades at prices ranging from $604.34 to $605.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
More UTHR filings
- SC 13G/A
Filed Nov 4, 2026
- 8-K
Filed Nov 4, 2026
- 10-Q
Filed Nov 4, 2026
- 4
Filed Nov 3, 2026
- 144
Filed Nov 2, 2026
- 4
Filed Nov 2, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.